

Supporting Information

for

**Diversity-oriented synthesis of dihydrobenzoxazepinones by coupling the
Ugi multicomponent reaction with a Mitsunobu cyclization**

Lisa Moni, Luca Banfi, Andrea Basso, Alice Brambilla and Renata Riva*

Address: Department of Chemistry and Industrial Chemistry, University of Genova, I-16146 Genova, Italy

E-mail: Renata Riva* - riva@chimica.unige.it

*Corresponding author

**Experimental procedure, characterization data and copies of ^1H and ^{13}C spectra
of all new compounds**

Table of Contents


1. Experimental details and characterization data of new compounds	S2
2. NMR Spectra of new compounds	S14

1) Experimental details and characterization of new compounds

General remarks


NMR spectra were taken at r.t. in CDCl_3 at 300 MHz (^1H), and 75 MHz (^{13}C), using, as internal standard, TMS (^1H NMR: 0.000 ppm) or the central peak of CDCl_3 (^{13}C : 77.02 ppm). Chemical shifts are reported in ppm (δ scale). Coupling constants are reported in Hertz. Peak assignments were made with the aid of gCOSY and gHSQC experiments. In ABX system, the proton A is considered upfield and B downfield. GC-MS were carried out using an HP-1 column (12 m long, 0.2 mm wide), electron impact at 70 eV, and a mass temperature of about 170°C. Only $m/z > 33$ were detected. All analyses were performed (unless otherwise stated) with a constant He flow of 0.9 ml/min with initial temp. of 100°C, init. time 2 min, rate 20°C/min, final temp. 280°C, inj. temp. 250°C, det. temp. 280°C. IR spectra were recorded as CHCl_3 solutions or directly on solid, oil or foamy samples, with the ATR (attenuated total reflectance) technique. TLC analyses were carried out on silica gel plates and viewed at UV (254 nm) and developed with Hanessian stain (dipping into a solution of $(\text{NH}_4)_4\text{MoO}_4 \cdot 4 \text{H}_2\text{O}$ (21 g) and $\text{Ce}(\text{SO}_4)_2 \cdot 4 \text{H}_2\text{O}$ (1 g) in H_2SO_4 (31 ml) and H_2O (469 ml) and warming) or, only to detect free amines after Staudinger reduction, with ninhydrin (900 mg of ninhydrin in 300 ml $n\text{BuOH}$ and 9 ml AcOH , followed by warming). R_f were measured after an elution of 7-9 cm. Column chromatographies were done with the "flash" methodology using 220-400 mesh silica. Petroleum ether (40-60°C) is abbreviated as PE. In extractive work-up, aqueous solutions were always reextracted thrice with the appropriate organic solvent. Organic extracts were always dried over Na_2SO_4 and filtered, before evaporation of the solvent under reduced pressure. All reactions using dry solvents were carried out under a nitrogen (or argon if specified) atmosphere. Petroleum ether (40-60°C) is abbreviated as PE. In extractive work-up, aqueous solutions were always re-extracted thrice with the appropriate organic solvent. Organic extracts were always dried over Na_2SO_4 and filtered, before evaporation of the solvent under reduced pressure. All reactions using dry solvents were carried out under a nitrogen atmosphere, unless otherwise stated.

(2-(Benzyloxy)phenyl)methanol



It was prepared in 94% yield from commercially available 2-(hydroxymethyl)phenol, following the reported procedure [1]. The physical and spectral data were in agreement with those reported [1-2].


1-(Azidomethyl)-2-(benzyloxy)benzene (2a)



A solution of 2-((benzyloxy)phenyl)methanol (2.00 g, 9.34 mmol) in dry dichloromethane (20 mL) was cooled to -30°C and treated with Et_3N (1.70 mL, 12.15 mmol) and methanesulphonyl chloride (868 μL , 11.21 mmol). The mixture was stirred at -30°C for 5 h and at r.t. for 30 min (due to

hydrolytic instability of the mesylate it is not possible to follow the reaction by TLC). Then the solvent was evaporated. The crude residue was taken up in dry DMF (20 mL) and treated with sodium azide (1.286 g, 19.62 mmol). The mixture was stirred at r.t. for 20 h. Then it was diluted with water (50 mL) and extracted three times with Et₂O. The organic phases were washed with water and brine, evaporated and chromatographed (PE/Et₂O 98:2 to 96:4) to give pure **2a** as a colourless oil (1.92 g, 86%). The physical and spectral data were in agreement with those reported [3].


1-(Azidomethyl)-2-(benzyloxy)-3-methoxybenzene (**2b**)



2b

It was prepared from known (2-(Benzyloxy)3-methoxyphenyl)methanol (in turn prepared in quantitative yield by reduction of the corresponding aldehyde [4]) following the same procedure employed for **2a**. White foam. Yield 81%. *R_f* 0.49 (PE/AcOEt 9:1). ¹H NMR (300 MHz, CDCl₃, 25 °C) δ 3.90 (3 H, s, CH₃); 4.26 (2 H, s, CH₂N₃); 5.07 (2 H, s, CH₂Ph), 6.90 (1 H, dd, *H*-4 or *H*-6, *J* 1.5, 7.8); 6.95 (1 H, dd, *H*-4 or *H*-6, *J* 1.5, 8.1); 7.08 (1 H, t, *H*-5, *J* 7.8); 7.29-7.48 (5 H, m, benzyl CH). ¹³C NMR (75 MHz, CDCl₃, 25 °C) δ 49.8 (CH₂N₃); 55.9 (OCH₃); 75.1 (CH₂Ph); 112.8, 121.6, 124.3, 128.1, 128.3 (x2), 128.4 (aromatic CH); 129.7, 137.5, 146.0, 152.8 (aromatic quat.). I.r. (ATR): ν_{max} 2091, 1587, 1497, 1479, 1454, 1439, 1376, 1342, 1275, 1214, 1180, 1077, 978, 915, 884, 860, 784, 747, 696, 612 cm⁻¹. HRMS (ESI+) *m/z*: [M + H]⁺ Calcd for C₁₅H₁₆N₃O₂ 270.1243; Found 270.1240.


(2-(Benzyloxy)-5-phenylphenyl)methanol (**6**)



6


A solution of (2-(benzyloxy)-5-bromophenyl)methanol [5] (400 mg, 1.36 mmol), phenylboronic acid (249.4 mg, 2.05 mmol) and PPh₃ (53.6 mg, 205 μmol) in dry THF (10 mL) is placed in a pressure tube. A solution of Cs₂CO₃ (889 mg, 2.73 mmol) in H₂O (2 mL) is added and the system is flushed with argon. After addition of the catalyst (Pd(OAc)₂) (15 mg, 78 μmol) the tube is sealed and heated at 90 °C in a pre-heated oil bath. After 4 h the system is cooled and the mixture poured into saturated aqueous NH₄Cl (140 mL) and extracted three times with CH₂Cl₂. Evaporation followed by chromatography (PE/Et₂O 66:34) gave pure **6** as a white solid (313 mg, 79%). M.p.: 100.5-101.2 °C. *R_f* 0.27 (PE/Et₂O 66:34). ¹H NMR (300 MHz, CDCl₃, 25 °C) δ 2.34 (1 H, t, OH, *J* 5.4); 4.80 (2 H, d, CH₂OH, *J* 5.4); 5.16 (2 H, s, CH₂Ph); 7.02 (1 H, d, *H*-3, *J* 8.1); 7.26-7.46 (8 H, m); 7.48 (1 H, dd, *H*-4, *J* 2.1, 8.1); 7.53-7.58 (3 H, m). ¹³C NMR (75 MHz, CDCl₃, 25 °C) δ 62.2 (CH₂OH); 70.2 (CH₂Ph); 112.0 (*C*-3); 126.8 (x3), 127.3 (x2), 127.4, 127.6, 128.2, 128.7 (x4) (other aromatic CH); 129.8, 134.1, 136.7, 140.6, 156.1 (aromatic quat.). I.r. (ATR): ν_{max} 3273, 3063, 3035, 2859, 1608, 1514, 1488, 1452, 1381, 1360, 1309, 1289, 1274, 1249, 1177, 1128, 1079, 1047, 1035, 1024, 1008, 920, 905, 891, 841, 803, 772, 759, 731, 691, 632, 618 cm⁻¹. GC-MS: *R_t* 13.27 min; *m/z* 290 (M⁺, 0.04%) 182 (28.5) 153 (5.0) 152 (5.5) 92 (8.3) 91 (100) 65 (10.1). HRMS (ESI+) *m/z*: [M + H]⁺ Calcd for C₂₀H₁₉O₂ 291.1385; Found 291.1381.

1-(Azidomethyl)-2-(benzyloxy)-5-phenylbenzene (2c)




It was prepared from **6** in 86% yield following the same procedure employed for **2a**. White solid. M.p.: 73.5-74.5 °C. R_f 0.36 (PE/Et₂O 97:3). ¹H NMR (300 MHz, CDCl₃, 25 °C) δ 4.48 (2 H, s, CH₂N₃); 5.17 (2 H, s, CH₂Ph), 7.04 (1 H, d, *H*-3, *J* 9.3); 7.27-7.60 (12 H, m, other aromatic CH). ¹³C NMR (75 MHz, CDCl₃, 25 °C) δ 50.2 (CH₂N₃); 70.3 (CH₂Ph); 112.2 (*C*-2), 124.6 (*C*-1), 126.8 (x2), 126.9, 127.3 (x2), 128.1, 128.2, 128.7 (x2), 128.78 (x2), 128.84 (other aromatic CH); 134.1, 136.7, 140.3, 156.1 (other aromatic quat.). I.r. (ATR): $\nu_{\max}$ 2116, 1610, 1586, 1508, 1484, 1462, 1456, 1450, 1383, 1350, 1295, 1279, 1271, 1250, 1242, 1228, 1179, 1134, 1077, 1054, 1015, 999, 951, 908, 899, 856, 843, 827, 767, 758, 740, 714, 696, 625, 605 cm⁻¹. GC-MS: R_t 13.39 min; m/z 315 (M⁺, 0.002%) 196 (7.9) 182 (8.1) 115 (5.1) 92 (9.3) 91 (100) 65 (12.7). HRMS (ESI+) m/z : [M + H]⁺ Calcd for C₂₀H₁₈N₃O 316.1450; Found 316.1451.

2-(Azidomethyl)-3-(benzyloxy)naphthalene (2d)




It was prepared in 98% yield from known (3-(benzyloxy)naphthalen-2-yl)methanol [6-7] following the same procedure employed for **2a**. In this case no chromatography was needed. White solid. M.p.: 68.8-72.2 °C. R_f 0.82 (PE/Et₂O 75:25). ¹H NMR (300 MHz, CDCl₃, 25 °C) δ 4.57 (2 H, s, CH₂N₃); 5.24 (2 H, s, CH₂Ph), 7.24 (1 H, s, *H*-4); 7.32-7.47 (5 H, m, benzyl CH); 7.47-7.53 (2 H, m, *H*-6 and *H*-7); 7.72 (1 H, d, *H*-5 or *H*-8, *J* 8.1); 7.77 (1 H, s, *H*-1); 7.79 (1 H, d, *H*-5 or *H*-8, *J* 8.1). ¹³C NMR (75 MHz, CDCl₃, 25 °C) δ 50.6 (CH₂N₃); 70.2 (CH₂Ph); 106.7 (*C*-4); 124.2, 126.6, 126.7, 127.4 (x2), 127.7, 128.1, 128.7 (x2), 129.3 (other aromatic CH); 125.8, 128.6, 134.4, 136.6, 154.7 (other aromatic quat.). I.r. (ATR): $\nu_{\max}$ 2095, 2081, 1634, 1602, 1506, 1466, 1455, 1435, 1399, 1380, 1345, 1282, 1243, 1181, 1159, 1105, 1008, 995, 925, 889, 863, 831, 762, 751, 722, 703, 689, 621 cm⁻¹. GC-MS: R_t 12.55 min; m/z 289 (M⁺, 9.3%) 261 (9.8) 260 (6.7) 170 (10.7) 156 (13.9) 128 (14) (7.9) 115 (7.0) 92 (7.9) 91 (100) 65 (11.4) 44 (11.3) 40 (9.9). HRMS (ESI+) m/z : [M + H]⁺ Calcd for C₁₈H₁₆N₃O 290.1293; Found 290.1296.

***N*-(*tert*-Butyl)-2-cyclohexyl-2-(3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)acetamide (10a)**



White solid. M.p.: 135.4-136.8 °C. R_f 0.32 (PE/AcOEt 80:20). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 0.79-1.02 (2 H, m); 1.07-1.52 (3 H, m); 1.21 (9 H, s, $(\text{C}(\text{CH}_3)_3)$); 1.57-1.83 (5 H, m); 2.06 (1 H, tq, CH-CH-C=O , J_t 3.2, J_q 11.0); 4.57 (1 H, d, CH-C=O , J 11.1); 4.64 and 4.72 (2 H, AB syst., H -5, J_{AB} 15.3); 4.71 and 4.81 (2 H, AB syst., H -2, J_{AB} 15.3); 5.74 (1 H, s, NH); 6.96-7.04 (2 H, m, H -9, H -7); 7.17-7.28 (2 H, m, H -7, H -8). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 25.4, 25.6, 26.2, 28.8, 29.6 (CH_2 of cyclohexyl); 28.4 ($\text{C}(\text{CH}_3)_3$); 35.6 (CH-CH-C=O); 43.9 (C-5); 51.3 ($\text{C}(\text{CH}_3)_3$); 61.9 (CH-C=O); 71.6 (C-2); 119.4 (C-9); 123.3 (C-7); 127.3 (C-5a); 129.5, 129.7 (C-8 and C-6); 157.2 (C-9a); 168.6, 169.6 (C=O). I.r. (CHCl_3): ν_{max} 3419, 2928, 2851, 1670, 1618, 1450, 1364, 1327, 1230, 1110, 1046 cm^{-1} . GC-MS: R_t 12.58 min; m/z 358 (M^+ , 3.6%) 286 (7.8) 285 (31.8) 258 (84.1) 257 (10.0) 203 (14.3) 198 (14.1) 197 (100) 176 (20.6) 164 (31.6) 163 (9.8) 162 (28.8) 154 (5.5) 148 (19.2) 147 (5.0) 141 (12.9) 134 (10.9) 123 (5.4) 122 (7.1) 121 (7.7) 120 (6.5) 119 (13.3) 118 (5.8) 115 (16.7) 112 (11.8) 110 (6.1) 107 (37.2) 106 (9.0) 98 (17.5) 95 (92.2) 93 (11.6) 91 (37.4) 89 (9.4) 85 (7.1) 81 (8.9) 80 (5.9) 78 (21.0) 77 (19.9) 67 (30.7) 65 (8.5) 57 (48.2) 55 (33.6) 42 (72.6) 41 (53.9). HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{31}\text{N}_2\text{O}_3$ 359.2335; Found 359.2336.


***N*-Cyclohexyl-2-(3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)-2-phenylacetamide (10b)**



White foam. R_f 0.64 (PE/AcOEt 50:50). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 1.00-1.20 (3 H, m); 1.20-1.45 (2 H, m); 1.52-1.75 (3 H, m); 1.78-2.02 (2 H, m); 3.84 (1 H, dtt, CHNH , J_t 3.7, 10.8, J_d 7.8); 4.25 (1 H, d, H -5, J 15.3); 4.68 and 4.87 (2 H, AB syst., H -2, J_{AB} 15.6); 4.78 (1 H, d, H -5, J 15.3); 5.90 (1 H, d, NH , J 7.8); 6.38 (1 H, s, CH-C=O); 6.63 (1 H, dd, H -6, J 7.5, 1.2); 6.87 (1 H, dt, H -7, J_t 7.4, J_d 0.9); 6.98 (1 H, d, H -9, J 7.5); 7.20 (1 H, dt, H -8, J_t 8.1, J_d 1.2); 7.33 (5 H, s). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 24.7 (x2), 25.4, 32.7, 32.9 (cyclohexyl CH); 45.8 (C-5); 48.6 (CHNH); 60.5 (CH-C=O); 72.0 (C-2); 119.5 (C-9); 123.5 (C-7); 128.3 (C-5a); 128.5 (C para of Ph); 128.8, 129.0 (C ortho and meta of Ph); 129.1 (C-6); 129.6 (C-8); 134.9 (quat. of Ph); 157.4 (C-9a); 168.0, 169.8 (C=O). I.r. (CHCl_3): ν_{max} 3413, 3330, 3001, 2925, 2852, 2702, 1660, 1488, 1450, 1321, 1219, 1022, 919, 661 cm^{-1} . GC-MS: R_t 12.203 min; m/z 378 (M^+ , 0.2%) 253 (11.4) 252 (24.3) 218 (16.9) 217 (100.0) 162 (13.2) 146 (10.7)


136 (14.1) 121 (5.8) 119 (11.3) 118 (50.3) 107 (8.3) 106 (9.4) 104 (8.5) 92 (9.6) 91 (55.9) 90 (7.4) 89 (7.0) 83 (5.8) 78 (7.0) 77 (10.2) 65 (4.7) 55 (12.8) 41 (9.5). HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd for C₂₃H₂₇N₂O₃ 379.2022; Found 379.2016.

2-(Benzo[d][1,3]dioxol-5-yl)-N-(tert-butyl)-2-(3-oxo-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)acetamide (10c)



White solid. M.p.: 194.9-195.9 °C. *R_f* 0.65 (PE/AcOEt 50:50). ¹H NMR (300 MHz, CDCl₃, 25 °C) δ 1.34 (9 H, s, C(CH₃)₃); 4.26 (1 H, d, *H*-5, *J* 15.6); 4.67 and 4.91 (2 H, AB syst., *H*-2, *J*_{AB} 15.5); 4.81 (1 H, d, *H*-5, *J* 15.6); 5.61 (1 H, s, NH); 5.97 and 5.98 (2 H, AB syst. OCH₂O, *J*_{AB} 1.4); 6.17 (1 H, s, CH-C=O); 6.68 (1 H, dd, *H*-6, *J* 7.5, 1.5); 6.76-6.85 (3 H, m, CH of benzodioxole); 6.90 (1 H, dt, *H*-7, *J*_t 7.5, *J*_d 1.2); 6.98 (1 H, dd, *H*-9, *J* 8.1, 1.2); 7.20 (1 H, dt, *H*-8, *J*_t 7.8, *J*_d 1.2). ¹³C NMR (75 MHz, CDCl₃, 25 °C) δ 28.6 (C(CH₃)₃); 45.7 (C-5); 51.9 (CNH); 60.7 (CH-C=O); 71.9 (C-2); 101.3 (O-C-O); 108.4, 109.6, 119.6 (CH benzodioxole); 122.8 (C-9); 123.3 (C-7); 127.9, 128.6 (C-5a and quat. benzodioxole); 129.1 (C-6); 129.7 (C-8); 147.7, 148.0 (quat. of benzodioxole); 157.4 (C-9a); 168.3, 169.7 (C=O). I.r. (ATR): *v*_{max} 3299, 2968, 1680, 1640, 1608, 1548, 1489, 1467, 1456, 1440, 1353, 1256, 1217, 1199, 1170, 1114, 1104, 1065, 1035, 1021, 938, 926, 862, 808, 797, 747, 727, 705, 650, 623 cm⁻¹. GC-MS: *R_t* 14.94 min; *m/z* 396 (M⁺, 7.2%) 323 (25.7) 297 (39.4) 296 (59.3) 235 (49.8) 217 (40.2) 190 (15.0) 179 (10.5) 176 (40.8) 175 (5.4) 163 (13.9) 162 (100) 161 (13.3) 150 (14.2) 149 (20.3) 148 (37.1) 147 (17.7) 146 (32.3) 136 (46.2) 135 (84.7) 134 (11.2) 133 (6.2) 132 (17.3) 121 (9.8) 120 (7.8) 119 (8.9) 118 (5.6) 107 (14.1) 105 (9.8) 104 (22.1) 93 (5.3) 92 (5.9) 91 (27.1) 90 (7.3) 89 (9.6) 79 (5.7) 78 (12.6) 77 (26.9) 76 (12.5) 65 (14.2) 63 (7.6) 57 (28.3) 51 (9.7) 44 (6.7) 42 (6.4) 41 (18.7) 40 (7.6) 39 (8.5). HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd for C₂₂H₂₅N₂O₅ 397.1763; Found 397.1758.


Ethyl 2-(2-(3-oxo-2,3-dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)-2-(3,4,5-trimethoxyphenyl)acetamido)acetate (10d)



White solid. M.p.: 143.6-149.7 °C. *R_f* 0.38 (PE/AcOEt 34:66). ¹H NMR (300 MHz, CDCl₃, 25 °C) δ 1.29 (3 H, t, CH₃CH₂, *J* 7.0); 3.70 (6 H, s, OCH₃); 3.84 (3 H, s, OCH₃); 3.93 (1 H, dd, CHHCO₂Et, *J* 5.1, 18.0); 4.07-4.30 (3 H, m, CH₂CH₃ and CHHCO₂Et); 4.18 (1 H, d, *H*-5, *J* 15.6); 4.64


and 5.02 (2 H, AB syst., *H*-2, J_{AB} 15.0); 4.94 (1 H, d, *H*-5, J 15.6); 6.37 (1 H, s, *CH*-C=O); 6.41 (1 H, broad s, *NH*); 6.57 (2 H, s, *CH* trimethoxyphenyl); 6.64 (1 H, dd, *H*-6, J 7.5, 1.2); 6.87 (1 H, dt, *H*-7, J_t 7.4, J_d 1.2); 6.98 (1 H, dd, *H*-9, J 8.1, 10.9); 7.19 (1 H, dt, *H*-8, J_t 7.8, J_d 1.5). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 14.2 (CH_3CH_2); 41.4 ($\text{CH}_2\text{CO}_2\text{Et}$); 46.4 (*C*-5); 51.8 (*CNH*); 56.1 (x2) (OCH_3); 60.9 (OCH_3); 61.6 (*CH*-C=O); 71.5 (*C*-2); 106.0 (*CH* trimethoxyphenyl); 119.6 (*C*-9); 123.1 (*C*-7); 127.2 (*C*-5a); 129.1 (*C*-6); 129.5 (quat. trimethoxyphenyl); 129.7 (*C*-8); 137.9, 153.4 (*C*-OMe); 157.2 (*C*-9a); 169.3, 169.5, 170.1 (*C*=O). I.r. (ATR): ν_{max} 3299, 2958, 1755, 1746, 1685, 1654, 1598, 1548, 1511, 1490, 1468, 1452, 1432, 1352, 1332, 1288, 1256, 1192, 1130, 1112, 1098, 1082, 1062, 1019, 1000, 958, 922, 864, 810, 783, 757, 737, 717, 703, 678, 645, 623 cm^{-1} . GC-MS (initial temp. 100°C, final temp. 290°C): R_f 13.76 min; m/z 472 (M^+ , 2.0%) 370 (12.1) 369 (49.6) 342 (19.2) 264 (16.6) 263 (100) 209 (9.8) 208 (60.2) 207 (17.1) 194 (7.2) 193 (26.6) 182 (7.7) 181 (16.1) 178 (10.8) 177 (38.1) 165 (5.6) 163 (6.5) 162 (14.1) 150 (9.6) 147 (8.7) 146 (18.3) 136 (5.3) 135 (7.7) 134 (6.8) 133 (7.4) 121 (5.8) 120 (10.9) 119 (9.5) 118 (8.2) 107 (16.9) 105 (5.4) 96 (7.1) 92 (5.5) 91 (35.6) 90 (6.8) 89 (7.7) 79 (11.6) 78 (12.9) 77 (13.1) 74 (6.6) 65 (7.8) 56 (7.9) 44 (57.7) 42 (8.5) 40 (50.3). HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{29}\text{N}_2\text{O}_8$ 473.1924; Found 473.1918.

***N*-Butyl-2-(3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)-2-phenylacetamide (10e)**




White solid. M.p.: 100.2–101.8 °C. R_f 0.35 (PE/AcOEt 75:25). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 0.90 (3 H, t, CH_3CH_2 , J 7.2); 1.23-1.37 (2 H, m, CH_2CH_3); 1.41-1.53 (2 H, m, $\text{CH}_2\text{CH}_2\text{CH}_3$); 3.20-3.43 (2 H, m, CH_2NH); 4.25 (1 H, d, *H*-5, J 15.3); 4.68 and 4.88 (2 H, AB syst., *H*-2, J_{AB} 15.6); 4.79 (1 H, d, *H*-5, J 15.3); 5.95 (1 H, broad t, *NH*); 6.38 (1 H, s, *CH*-C=O); 6.63 (1 H, dd, *H*-6, J 7.8, 1.5); 6.88 (1 H, dt, *H*-7, J_t 7.2, J_d 0.9); 6.99 (1 H, dd, *H*-9, J 8.1, 1.6); 7.20 (1 H, dt, *H*-8, J_t 8.1, J_d 1.5); 7.30-7.38 (5 H, m). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 13.7 (CH_3); 20.0 (CH_2CH_3); 31.3 ($\text{CH}_2\text{CH}_2\text{CH}_3$); 39.3 (CH_2NH); 45.7 (*C*-5); 60.4 (*CH*-C=O); 71.9 (*C*-2); 119.4 (*C*-9); 123.4 (*C*-7); 128.3 (*C*-5a); 128.4 (*C* para of Ph); 128.7, 128.9 (*C* ortho and meta of Ph); 129.0 (*C*-6); 129.5 (*C*-8); 134.8 (quat. of Ph); 157.3 (*C*-9a); 168.9, 169.7 (*C*=O). I.r. (ATR): ν_{max} 3282, 2956, 1666, 1645, 1558, 1491, 1474, 1451, 1430, 1364, 1339, 1307, 1262, 1234, 1219, 1199, 1173, 1156, 1115, 1065, 1043, 1025, 971, 953, 925, 862, 751, 735, 697, 648, 609 cm^{-1} . HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{25}\text{N}_2\text{O}_3$ 353.1865; Found 353.1871.

***N*-Cyclohexyl-2-(2-methylpropyl)-2-(3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)acetamide (10f)**




White solid. M.p.: 94.8-95.7 °C. R_f 0.58 (PE/AcOEt 60:40). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 0.77-0.96 (2 H, m); 0.886 (3 H, d, CH_3 , J 6.6); 0.893 (3 H, d, CH_3 , J 6.6); 1.00-1.87 (11 H, m); 3.64 (1 H, dtt, CHNH , J_t 3.7, 12.0, J_d 8.0); 4.51 and 4.59 (2 H, AB syst., H -5, J_{AB} 15.3); 4.75 and 4.79 (2 H, AB syst., H -2, J_{AB} 15.3); 5.13 (1 H, dd, CH-C=O , J 6.6, 9.0); 5.78 (1 H, d, NH , J 8.0); 6.99-7.06 (2 H, m, H -9, H -7); 7.16 (1 H, dd, H -6, J 1.6, 8.0); 7.27 (1 H, dt, H -8, J_d 1.6, J_t 7.7). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 22.0, 22.9 (CH_3); 24.5, 24.6, 25.3, 32.4, 32.6 (CH_2 of cyclohexyl); 24.7 ($\text{CH}(\text{CH}_3)_2$); 36.8 ($\text{CH}_2\text{-CH-C=O}$); 44.2 (C-5); 48.0 (CHNH); 54.8 (CH-C=O); 71.6 (C-2); 119.5 (C-9); 123.3 (C-7); 126.9 (C-5a); 129.1 (C-6); 129.9 (C-8); 157.2 (C-9a); 169.1, 169.6 (C=O). I.r. (CHCl_3): ν_{max} 3419, 2996, 2931, 2853, 1663, 1619, 1488, 1451, 1347, 1325, 1191, 1111, 1055, 697 cm^{-1} . HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{31}\text{N}_2\text{O}_3$ 359.2335; Found 359.2339.

2-Ethyl-2-(9-methoxy-3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)-*N*-methylacetamide (10g)




White solid. M.p.: 163.6-166.0 °C. R_f 0.26 (PE/AcOEt 1:10). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 0.88 (3 H, t, CH_3CH_2 , J 7.3); 1.78 (1 H, ddq, CHHCH_3 , J_d 8.4, 14.5, J_q 7.3); 2.09 (1 H, d of quint, CHHC_3 , J_d 14.5, J_{quint} 7.2); 2.73 (3 H, d, CH_3NH , J 4.8); 3.88 (3 H, s, OCH_3); 4.49 and 4.55 (2 H, AB syst., H -5, J_{AB} 14.9); 4.75 and 4.79 (2 H, AB syst., H -2, J_{AB} 16.0); 5.02 (1 H, dd, CH-C=O , J 6.9, 8.4); 5.94 (1 H, broad s, NH); 6.80 (1 H, dd, H -8 or H -6, J 7.5, 1.5); 6.92 (1 H, dd, H -6 or H -8, J 8.1, 1.3); 7.03 (1 H, dd, H -7, J 7.5, 8.1). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 10.4 (CH_3CH_2); 21.4 (CH_3CH_2); 26.1 (CH_3NH); 43.5 (C-5); 56.0 (CH_3O); 58.2 (CH-C=O); 71.2 (C-2); 112.6, 120.3 (C-8 , C-6); 124.4 (C-7); 130.8, 146.2, 150.9 (aromatic quat.); 170.0, 170.6 (C=O). I.r. (ATR): ν_{max} 3295, 2965, 1677, 1636, 1582, 1563, 1480, 1435, 1417, 1386, 1365, 1337, 1302, 1266, 1240, 1215, 1197, 1183, 1162, 1092, 1081, 1052, 1028, 990, 955, 782, 766, 751, 735, 689, 630 cm^{-1} . GC-MS: R_t 11.62 min; m/z 292 (M^+ , 1.1%) 262 (13.3) 234 (6.0) 192 (31.5) 164 (5.3) 137 (7.4) 101 (8.0) 86 (15.4) 77 (7.6) 71 (5.6) 70 (100) 65 (8.7) 58 (17.0) 42 (13.0) 41 (9.3) 39 (5.1). HRMS (ESI+) m/z : $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{NaO}_4$ 315.1321; Found 315.1315.

***N*-Benzyl-2-(*tert*-butyl)-2-(9-methoxy-3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)acetamide (10h)**



White solid. M.p.: 157.8-160.1 °C. R_f 0.53 (PE/AcOEt 66:34). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 1.11 (9 H, s, $\text{C}(\text{CH}_3)_3$); 3.88 (3 H, s, OCH_3); 4.23 and 4.44 (2 H, AB part of an ABX syst., CH_2Ph , J_{AB} 14.7, J_{AX} 5.4, J_{BX} 6.0); 4.69 (1 H, d, *H*-5, J 15.3); 4.88 (1 H, d, *H*-5, J 15.3); 4.87 and 4.94 (2 H, AB syst., *H*-2, J_{AB} 16.0); 4.97 (1 H, s, $\text{CH}-\text{C}=\text{O}$); 6.16 (1 H, t, *NH*, J 5.7); 6.79 (1 H, dd, *H*-8 or *H*-6, J 7.5, 1.8); 6.89 (1 H, dd, *H*-6 or *H*-8, J 8.2, 1.6); 6.96 (1 H, dd, *H*-7, J 7.5, 8.2); 7.09-7.15 (2 H, m); 7.22-7.30 (3 H, m). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 27.6 ($\text{C}(\text{CH}_3)_3$); 35.7 ($\text{C}(\text{CH}_3)_3$); 43.3 (CH_2Ph); 45.8 (*C*-5); 56.0 (CH_3O); 62.7 ($\text{CH}-\text{C}=\text{O}$); 71.8 (*C*-2); 112.2, 121.2 (*C*-8, *C*-6); 123.6 (*C*-7); 127.5, 127.7 (x2), 128.7 (*CH* benzyl); 129.3, 137.7, 146.4, 150.5 (aromatic quat.); 169.0, 170.2 ($\text{C}=\text{O}$). I.r. (ATR): ν_{max} 3332, 2970, 1673, 1621, 1543, 1492, 1464, 1424, 1366, 1336, 1311, 1292, 1270, 1207, 1184, 1080, 1065, 1054, 1044, 1031, 785, 754, 730, 700, 650, 632 cm^{-1} . GC-MS: R_t 15.01 min; m/z 396 (M^+ , 0.9%) 290 (10.1) 289 (56.1) 262 (20.2) 233 (13.7) 205 (10.4) 193 (6.5) 192 (54.0) 191 (7.0) 190 (42.9) 178 (5.5) 164 (7.4) 162 (6.1) 149 (12.3) 137 (16.7) 136 (25.0) 135 (9.5) 107 (13.3) 106 (13.3) 105 (8.0) 98 (40.4) 92 (8.4) 91 (100) 86 (9.4) 79 (9.0) 78 (6.2) 77 (13.4) 69 (18.9) 65 (17.2) 57 (8.3) 56 (10.8) 51 (6.1) 42 (12.4) 41 (18.0) 39 (6.0). HRMS (ESI+) m/z : $[\text{M} + \text{Na}]^+$ Calcd for $\text{C}_{23}\text{H}_{28}\text{N}_2\text{NaO}_4$ 419.1947; Found 419.1951.


***N*-(*tert*-Butyl)-2-(9-methoxy-3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)-2-phenylacetamide (10i)**



White solid. M.p.: 180.8-181.5 °C. R_f 0.29 (PE/AcOEt 66:34). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 1.37 (9 H, s, $\text{C}(\text{CH}_3)_3$); 3.85 (3 H, s, OCH_3); 4.17 (1 H, d, *H*-5, J 15.0); 4.68 and 4.94 (2 H, AB syst., *H*-2, J_{AB} 16.0); 4.84 (1 H, d, *H*-5, J 15.0); 5.64 (1 H, s, *NH*); 6.12 (1 H, m, *H*-6); 6.31 (1 H, s, $\text{CH}-\text{C}=\text{O}$); 6.78-6.86 (2 H, m, *H*-7 and *H*-8); 7.30-7.40 (5 H, m). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 28.7 ($\text{C}(\text{CH}_3)_3$); 45.1 (*C*-5); 51.9 (*CNH*); 55.9 (OCH_3); 60.9 ($\text{CH}-\text{C}=\text{O}$); 72.2 (*C*-2); 112.2 (*C*-8); 120.4 (*C*-6); 123.9 (*C*-7); 128.5, 128.8 (x2), 129.2 (x2) (*CH* of phenyl); 131.3 (*C*-5a); 135.1 (quat. of phenyl); 146.3, 150.7 (*C*-9, *C*-9a); 168.4, 169.7 ($\text{C}=\text{O}$). I.r. (ATR): ν_{max} 3298, 2957, 1684, 1610, 1548, 1490, 1481, 1472, 1455, 1434, 1419, 1363, 1314, 1288, 1276, 1266, 1224, 1209, 1187, 1098, 1083, 1062, 1033, 952, 821, 783, 751, 718, 702, 679, 646, 623 cm^{-1} . GC-MS: R_t 13.94 min; m/z 382 (M^+ , 0.5%) 283 (10.0) 282 (14.6) 193 (7.1) 192 (64.3) 191 (78.3) 178 (7.1) 164 (6.7) 151 (19.0) 147 (6.2) 146 (11.9) 138 (8.6)


137 (17.5) 136 (19.7) 135 (39.5) 119 (15.6) 118 (100) 117 (5.3) 107 (10.2) 106 (18.8) 105 (8.1) 104 (11.2) 92 (10.6) 91 (85.0) 90 (10.4) 89 (6.5) 79 (9.6) 78 (6.6) 77 (16.1) 65 (14.4) 57 (24.4) 51 (6.3) 42 (5.6) 41 (14.7) 39 (7.0). HRMS (ESI+) m/z : $[M + H]^+$ Calcd for $C_{22}H_{27}N_2O_4$ 383.1971; Found 383.1976.

***N*-(2,6-Dimethylphenyl)-2-(9-methoxy-3-oxo-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)-2-phenylacetamide (10j)**



White solid. M.p.: 176.0-180.0 °C. R_f 0.26 (PE/AcOEt 50:50). 1H NMR (300 MHz, $CDCl_3$, 25 °C) δ 2.16 (6 H, s, CH_3Ar); 3.85 (3 H, s, OCH_3); 4.32 (1 H, d, *H*-5, J 14.7); 4.73 and 4.84 (2 H, AB syst., *H*-2, J_{AB} 16.2); 4.77 (1 H, d, *H*-5, J 15.0); 6.28 (1 H, apparent dd, *H*-6, J 3.3, 6.0); 6.64 (1 H, s, $CH-C=O$); 6.80-6.90 (2 H, m, *H*-7 and *H*-8); 7.00-7.12 (3 H, m); 7.37-7.45 (3 H, m); 7.47-7.53 (2 H, m); 7.61 (1 H, s, *NH*). ^{13}C NMR (75 MHz, $CDCl_3$, 25 °C) δ 18.4 ($ArCH_3$); 45.0 (*C*-5); 55.9 (OCH_3); 60.7 ($CH-C=O$); 72.3 (*C*-2); 112.3 (*C*-8); 120.6 (*C*-6); 124.2 (*C*-7); 127.5, 128.2 (x2), 128.7, 128.9 (x2), 129.2 (x2) (CH of phenyl and dimethylphenyl); 131.4 (*C*-5a); 133.2, 134.3, 135.4 (x2) (quat. of phenyl and dimethylphenyl); 146.3, 150.7 (*C*-9, *C*-9a); 167.6, 170.1 ($C=O$). I.r. (ATR): ν_{max} 3253, 2924, 1668, 1615, 1489, 1467, 1377, 1310, 1267, 1206, 1163, 1079, 1052, 958, 918, 824, 768, 720, 698 cm^{-1} . GC-MS (initial temp. 100°C, final temp. 290°C): R_t 14.26 min; m/z 430 (M^+ , 0.5%) 310 (9.5) 309 (6.0) 282 (17.0) 240 (13.2) 239 (69.6) 193 (5.6) 192 (40.8) 164 (5.4) 151 (7.1) 149 (7.4) 148 (48.7) 147 (5.5) 146 (9.1) 137 (14.1) 136 (14.0) 135 (9.5) 132 (5.1) 121 (10.2) 120 (9.7) 119 (14.3) 118 (95.7) 117 (5.8) 107 (10.4) 106 (15.8) 105 (14.7) 104 (11.5) 92 (11.8) 91 (100) 90 (12.6) 89 (7.1) 79 (10.6) 78 (8.8) 77 (25.2) 65 (15.1) 51 (9.1) 44 (9.2) 40 (7.9) 39 (7.2). HRMS (ESI+) m/z : $[M + H]^+$ Calcd for $C_{26}H_{27}N_2O_4$ 431.1971; Found 431.1973.


***N*-(*tert*-Butyl)-2-cyclohexyl-2-(3-oxo-7-phenyl-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)acetamide (10k)**



White solid. M.p.: 135.2-136.0 °C. R_f 0.61 (PE/AcOEt 66:34). 1H NMR (300 MHz, $CDCl_3$, 25 °C) δ 0.80-1.04 (3 H, m); 1.18 (9 H, s, $C(CH_3)_3$); 1.10-1.38 (2 H, m); 1.45-1.85 (5 H, m); 2.10 (1 H, tq, $CHCH-C=O$, J_t 3.3, J_q 11.1); 4.58 (1 H, d, $CH-C=O$, J 11.1); 4.68 and 4.81 (2 H, AB syst., *H*-5, J_{AB} 15.4); 4.75 and 4.89 (2 H, AB syst., *H*-2, J_{AB} 15.0); 5.68 (1 H, s, *NH*); 7.04 (1 H, d, *H*-9, J 8.1); 7.32 (1 H, dt, *H*-8, J_d 7.2, J_t 1.3); 7.38-7.55 (5


H, m). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 25.5, 25.6, 26.3, 28.9, 29.8 (cyclohexyl CH_2); 28.4 ($\text{C}(\text{CH}_3)_3$); 35.6 (cyclohexyl CH); 44.3 (C-5); 51.4 (CNH); 62.0 ($\text{CH}-\text{C}=\text{O}$); 71.5 (C-2); 119.8 (C-9); 126.8 (x2), 126.9, 127.2, 128.3 (x2), 128.8 (x2) (other aromatic CH and C-5a); 136.3, 140.0, 156.7 (quat.); 168.6, 169.6 (C=O). I.r. (ATR): ν_{max} 3328, 2927, 1647, 1622, 1544, 1510, 1484, 1451, 1406, 1391, 1363, 1329, 1258, 1226, 1193, 1178, 1123, 1063, 1023, 892, 826, 761, 718, 697, 651 cm^{-1} . GC-MS: R_f 13.33 min; m/z 238 ($\text{M}^+ - 196$, 3.4%) 197 (15.7) 182 (5.9) 165 (5.7) 154 (8.4) 153 (10.6) 152 (9.5) 141 (6.9) 128 (6.2) 124 (9.3) 115 (15.7) 112 (10.7) 111 (6.0) 110 (5.8) 98 (16.6) 96 (9.4) 95 (84.6) 94 (6.0) 93 (11.2) 91 (5.2) 85 (11.2) 82 (6.0) 81 (10.8) 80 (7.7) 79 (6.5) 77 (11.3) 68 (11.2) 67 (32.1) 59 (8.6) 58 (17.7) 57 (61.3) 56 (17.1) 55 (37.2) 54 (5.8) 53 (8.9) 44 (19.8) 43 (15.2) 42 (100) 41 (63.0) 40 (10.7) 39 (9.7). HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{27}\text{H}_{35}\text{N}_2\text{O}_3$ 435.2648; Found 435.2649.

***N*-(2,6-Dimethylphenyl)-2-isobutyl-2-(3-oxo-7-phenyl-2,3-dihydrobenzo[*f*][1,4]oxazepin-4(5*H*)-yl)acetamide (10l)**




White solid. M.p.: 165.3-167.7 °C. R_f 0.41 (PE/AcOEt 75:25). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 0.97 (6 H, d, CH_3CH , J 6.6); 1.55-1.67 (1 H, m, $\text{CH}(\text{CH}_3)_2$); 1.82 (1 H, ddd, $\text{CHH}-i\text{Pr}$, J 6.0, 8.1, 14.1); 2.01 (1 H, dt, $\text{CHH}-i\text{Pr}$, J_t 7.5, J_d 14.1); 2.01 (6 H, s, CH_3Ar); 4.71 (1 H, s, *H*-5); 4.82 and 4.87 (2 H, AB syst., *H*-2, J_{AB} 15.3); 5.40 (1 H, t, $\text{CH}-\text{C}=\text{O}$, J 7.5); 6.96-7.10 (3 H, m); 7.11 (1 H, d, *H*-9, J 8.4); 7.28-7.46 (6 H, m); 7.50 (1 H, dd, *H*-8, J 2.1, 8.4). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 18.1 (CH_3Ar); 22.4, 22.8 (CH_3CH); 25.1 ($\text{CH}(\text{CH}_3)_2$); 36.7 (CH_2iPr); 44.5 (C-5); 54.9 ($\text{CH}-\text{C}=\text{O}$); 72.0 (C-2); 120.1 (C-9); 126.9 (x2), 127.3 (x2), 127.6, 127.9, 128.1 (x2), 128.8 (x2) (other aromatic CH); 128.7, 133.3, 135.0 (x2), 137.1, 140.0, 156.9 (aromatic quat.); 168.5, 170.2 (C=O). I.r. (ATR): ν_{max} 3255, 3028, 2961, 2916, 2872, 1663, 1645, 1524, 1512, 1481, 1466, 1445, 1431, 1403, 1379, 1365, 1331, 1282, 1238, 1219, 1208, 1187, 1169, 1130, 1121, 1070, 1046, 1027, 1021, 944, 827, 790, 768, 760, 711, 694, 669 cm^{-1} . GC-MS: R_f 9.50 min; m/z 336 ($\text{M}^+ - 120$, 2.0%) 253 (23.0) 252 (6.0) 251 (72.1) 211 (5.9) 209 (18.4) 181 (14.0) 126 (8.8) 125 (7.4) 124 (26.3) 123 (5.6) 89 (43.0) 63 (16.2) 62 (7.9) 41 (100) 39 (19.3). HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{29}\text{H}_{33}\text{N}_2\text{O}_3$ 457.2491; Found 457.2488.

N-Butyl-2-(3-oxo-2,3-dihydronaphtho[2,3-*f*][1,4]oxazepin-4(5*H*)-yl)-2-(3,4,5-trimethoxyphenyl)acetamide (10m)



White solid. M.p.: 65.2-70.5 °C. R_f 0.34 (PE/AcOEt 43:57). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 0.88 (3 H, t, CH_3CH_2 , J 7.2); 1.32 (2 H, hexuplet, $\text{CH}_2\text{CH}_2\text{CH}_3$, J 7.4); 1.43-1.56 (2 H, m, $\text{CH}_2\text{CH}_2\text{NH}$); 3.22-3.47 (2 H, m, CH_2NH); 3.68 (6 H, s, CH_3O); 3.87 (3 H, s, CH_3O); 4.42 (1 H, d, *H*-5, J 15.0); 4.74 and 4.97 (2 H, AB syst., *H*-2, J_{AB} 16.2); 4.99 (1 H, d, *H*-5, J 15.0); 5.95 (1 H, t, *NH*, J 5.5); 6.29 (1 H, s, *CH*-C=O); 6.56 (2 H, s, *CH* of trimethoxyphenyl); 7.18 (1 H, s, *H*-11 or *H*-6); 7.32-7.50 (2 H, m, *H*-8, *H*-9); 7.47 (1 H, s, *H*-6 or *H*-11); 7.65 (1 H, d, *H*-10 or *H*-7, J 8.1); 7.73 (1 H, d, *H*-10 or *H*-7, J 7.8). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 13.7 (CH_3CH_2); 20.0 (CH_3CH_2); 31.5 ($\text{CH}_2\text{CH}_2\text{NH}$); 39.4 (CH_2NH); 45.7 (*C*-5); 56.1 (x2), 60.9 (OCH_3); 60.9 (*CH*-C=O); 73.3 (*C*-2); 106.3 (*CH* trimethoxyphenyl); 116.3 (*C*-6 or *C*-11); 125.4 (*C*-8 or *C*-9); 126.7 (*C*-8 or *C*-9) 127.0, 127.7 (*C*-7 and *C*-10); 128.1 (*C*-6 or *C*-11); 129.8, 130.0, 130.3, 134.2, 138.2, 153.5 (x2), 155.3 (quat.); 168.8, 169.8 (*C*=O). I.r. (ATR): ν_{max} 3308, 2961, 1659, 1635, 1590, 1543, 1506, 1456, 1419, 1368, 1332, 1247, 1154, 1125, 1111, 1007, 926, 869, 796, 750, 733, 701, 673, 644, 619 cm^{-1} . HRMS (ESI+) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{28}\text{H}_{33}\text{N}_2\text{O}_6$ 493.2339; Found 493.2334.

N-Benzyl-2-(*tert*-butyl)-2-(3-oxo-2,3-dihydronaphtho[2,3-*f*][1,4]oxazepin-4(5*H*)-yl)acetamide (10n)



White solid. M.p.: 145.8-148.4 °C. R_f 0.32 (PE/AcOEt 75:25). ^1H NMR (300 MHz, CDCl_3 , 25 °C) δ 1.16 (9 H, s, $\text{C}(\text{CH}_3)_3$); 4.23 and 4.40 (2 H, AB part of an ABX syst., CH_2Ph , J_{AB} 14.6, J_{AX} 5.5, J_{BX} 6.0); 4.66 and 4.95 (2 H, AB syst., *H*-2, J_{AB} 15.6); 4.98 (2 H, s, *CH*-C=O); 5.10 (1 H, s, *H*-5); 6.10 (1 H, t, *NH*, J 5.7); 6.98-7.04 (2 H, m); 7.06-7.15 (3 H, m); 7.41 (1 H, dt, *H*-8 or *H*-9, J_d 1.2, J_t 7.5); 7.46 (1 H, s, *H*-6 or *H*-11); 7.41 (1 H, dt, *H*-8 or *H*-9, J_d 1.2, J_t 7.5); 7.74 (1 H, s, *H*-6 or *H*-11); 7.76 (1 H, d, *H*-7 or *H*-10, J 8.1); 7.78 (1 H, d, *H*-7 or *H*-10, J 7.8). ^{13}C NMR (75 MHz, CDCl_3 , 25 °C) δ 27.7 ($\text{C}(\text{CH}_3)_3$); 35.8 ($\text{C}(\text{CH}_3)_3$); 43.3 (CH_2NH); 46.1 (*C*-5); 62.8 (*CH*-C=O); 72.8 (*C*-2); 115.9 (*C*-6 or *C*-11); 125.2 (*C*-8 or *C*-9); 126.8 (*C*-8 or *C*-9) 127.0, 127.4 (*C*-7 and *C*-10); 127.6 (x2), 128.6 (x2), 128.9 (*CH* benzyl); 128.0 (*C*-6 or *C*-11); 128.9, 130.3, 134.4, 137.5, 155.3 (quat.); 168.9, 170.3 (*C*=O). I.r. (ATR): ν_{max} 3299, 2959, 1646, 1616, 1541, 1507, 1467, 1340, 1242, 1158, 1112, 1039, 1016, 963, 874, 747, 698, 672, 619 cm^{-1} . GC-MS: R_t 13.66 min; m/z 416 (M^+ , 2.6%) 310 (15.4) 309 (71.3) 282 (18.7) 281 (5.8) 253 (15.6) 213 (13.4) 212 (89.9) 205 (5.4) 198 (6.4) 197 (6.2) 191 (6.8) 190 (42.4) 184 (16.2) 183 (5.4) 182 (6.8) 170 (6.7) 169 (21.4) 157 (21.0) 156 (18.3) 142 (6.1) 141 (29.8) 139 (12.5) 129 (

8.9) 128 (39.2) 127 (10.8) 115 (10.8) 106 (9.2) 98 (41.2) 92 (8.2) 91 (100) 86 (10.9) 83 (6.9) 77 (6.3) 69 (24.7) 65 (9.4) 57 (10.1) 56 (13.1) 55 (5.6) 44 (9.8) 43 (5.9) 42 (9.7) 41 (23.7) 40 (9.0) 39 (5.3). HRMS (ESI+) m/z: [M + H]⁺ Calcd for C₂₆H₂₉N₂O₃ 417.2178; Found 417.2179.

REFERENCES

- [1] Lee, J.; Lee, J.-H.; Kim, S. Y.; Perry, N. A.; Lewin, N. E.; Ayres, J. A.; Blumberg, P. M. *Bioorg. Med. Chem.* **2006**, *14*, 2022-2031.
- [2] Somu, R. V.; Boshoff, H.; Qiao, C.; Bennett, E. M.; Barry, C. E.; Aldrich, C. C. *J. Med. Chem.* **2005**, *49*, 31-34.
- [3] Barluenga, J.; Tomas-Gamasa, M.; Valdes, C. *Angew. Chem., Int. Ed.* **2012**, *51*, 5950-5952.
- [4] Nawrat, C. C.; Palmer, L. I.; Blake, A. J.; Moody, C. J. *J. Org. Chem.* **2013**, *78*, 5587-5603.
- [5] a) Shetty, R.; Moffett, K. K. *Tetrahedron Lett.* **2006**, *47*, 8021-8024. b) DeNinno, M. P.; Masamune, H.; Scott, R. W.,
Patent: US2004/198693 A1, **2004**.
- [6] Ahn, J. H.; Cho, S. Y.; Ha, J. D.; Chu, S. Y.; Jung, S. H.; Jung, Y. S.; Baek, J. Y.; Choi, I. K.; Shin, E. Y.; Kang, S. K.; Kim, S. S.; Cheon, H. G.; Yang, S.-D.; Choi, J.-K. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1941-1946.
- [7] Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. *J. Med. Chem.* **2008**, *51*, 6138-6149.

2) ^1H AND ^{13}C NMR SPECTRA OF ALL NEW COMPOUNDS

